Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14016077 | 0.91 | CETP (0.60) | CETPNR1I2 | |
| SCHEMBL13395444 | 0.91 | CETP (0.54) | CETPNR1I2 | |
| SCHEMBL17546257 | 0.89 | CETP (0.66) | CETPNR1I2 | |
| SCHEMBL531553 | 0.89 | CETP (0.63) | CETPNR1I2 | |
| SCHEMBL20794179 | 0.89 | CETP (0.63) | CETPNR1I2 | |
| SCHEMBL9957610 | 0.88 | CETP (0.62) | CETPNR1I2 | |
| SCHEMBL531582 | 0.88 | CETP (0.64) | CETPNR1I2 | |
| SCHEMBL29786762 | 0.88 | CETP (0.64) | CETPNR1I2 | |
| SCHEMBL9955359 | 0.88 | CETP (0.62) | CETPNR1I2 | |
| SCHEMBL14016073 | 0.86 | CETP (0.48) | CETPNR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2957342-B1 | METHOD FOR PRODUCING OPTICALLY ACTIVE ANTI-1,2-NITROALKANOL COMPOUND | MICROBIAL CHEM RES FOUND (JP) | 2020-07-29 | — | — | EP | disclosed |
| US-10300471-B2 | Ruthenium-catalyzed synthesis of biaryl compounds in water | CHICAGO DISCOVERY SOLUTIONS, LLC | 2019-05-28 | — | — | US | disclosed |
| US-9901913-B2 | Catalyst and method for producing optically active anti-1,2-nitroalkanol compound | MICROBIAL CHEMISTRY RESEARCH FOUNDATION (JP) | 2018-02-27 | — | — | US | disclosed |
| US-9901913-B2 | Catalyst and method for producing optically active anti-1,2-nitroalkanol compound | MICROBIAL CHEMISTRY RESEARCH FOUNDATION (JP) | 2018-02-27 | — | — | US | disclosed |
| US-20160263565-A1 | RUTHENIUM-CATALYZED SYNTHESIS OF BIARYL COMPOUNDS IN WATER | CHICAGO DISCOVERY SOLUTIONS, LLC (US) | 2016-09-15 | — | — | US | disclosed |
| EP-2985022-A1 | PROCESS FOR SYNTHESIZING A CETP INHIBITOR | Merck Sharp & Dohme Corp. (US) | 2016-02-17 | — | — | EP | disclosed |
| US-20150375219-A1 | Catalyst and Method for Producing Optically Active Anti-1,2-Nitroalkanol Compound | Microbial Chemistry Rsearch Fiundation (JP) | 2015-12-31 | — | — | US | disclosed |
| EP-2957342-A1 | CATALYST AND METHOD FOR PRODUCING OPTICALLY ACTIVE ANTI-1,2-NITROALKANOL COMPOUND | Microbial Chemistry Research Foundation (JP) | 2015-12-23 | — | — | EP | disclosed |
| US-9212118-B2 | Synthesis of intermediates for preparing anacetrapib and derivatives thereof | LEK PHARMACEUTICALS D.D. (SI) | 2015-12-15 | — | — | US | disclosed |
| US-9212118-B2 | Synthesis of intermediates for preparing anacetrapib and derivatives thereof | LEK PHARMACEUTICALS D.D. (SI) | 2015-12-15 | — | — | US | disclosed |
| US-20100099716-A1 | CETP INHIBITORS | MERCK SHARP & DOHME LLC | 2010-04-22 | — | — | US | disclosed |
| US-20100041724-A1 | Process For Synthesizing A CETP Inhibitor | MERCK SHARP & DOHME LLC | 2010-02-18 | — | — | US | disclosed |
| US-20100041724-A1 | Process For Synthesizing A CETP Inhibitor | MERCK SHARP & DOHME LLC | 2010-02-18 | — | — | US | disclosed |
| US-7652049-B2 | 1-benzyl-4-[4'-fluoro-5'-isopropyl-2'-methoxy-4-(trifluoromethyl)biphenyl-2-yl]imidazolidin-2-one; cholesteryl ester transfer protein inhibitor; raising HDL-cholesterol, reducing LDL-cholesterol; atherosclerosis; antiinflammatory agent; synergistic mixture with other active ingredients | MERCK & CO., INC. (US) | 2010-01-26 | — | — | US | disclosed |
| US-7652049-B2 | 1-benzyl-4-[4'-fluoro-5'-isopropyl-2'-methoxy-4-(trifluoromethyl)biphenyl-2-yl]imidazolidin-2-one; cholesteryl ester transfer protein inhibitor; raising HDL-cholesterol, reducing LDL-cholesterol; atherosclerosis; antiinflammatory agent; synergistic mixture with other active ingredients | MERCK & CO., INC. (US) | 2010-01-26 | — | — | US | disclosed |
| US-20080119476-A1 | Cetp Inhibitors | ALI AMJAD | 2008-05-22 | — | — | US | disclosed |
| US-20080119476-A1 | Cetp Inhibitors | ALI AMJAD | 2008-05-22 | — | — | US | disclosed |
| WO-2007136672-A2 | SYNTHESIS OF A BIARYL SYNTHETIC INTERMEDIATE | MERCK & CO., INC. (US) | 2007-11-29 | — | — | WO | disclosed |
| WO-2007092642-A2 | POLYMER FORMULATIONS OF CETP INHIBITORS | MERCK & CO., INC. (US) | 2007-08-16 | — | — | WO | disclosed |
| WO-2007005572-A1 | PROCESS FOR SYNTHESIZING A CETP INHIBITOR | MERCK & CO., INC. (US) | 2007-01-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150375219-A1 | Catalyst and Method for Producing Optically Active Anti-1,2-Nitroalkanol Compound | SCN1A, SCN1B, NOS1 | CETP 4308/4885NR1I2 2580/4885 |
| US-20080119476-A1 | Cetp Inhibitors | CETP, APOB, MTTP | CETP 1/4885NR1I2 67/4885 |
| US-10300471-B2 | Ruthenium-catalyzed synthesis of biaryl compounds in water | RUVBL2, RUVBL1, CYP2W1 | CETP 4403/4885NR1I2 767/4885 |
| US-20100041724-A1 | Process For Synthesizing A CETP Inhibitor | CETP, MTTP, CTDSP1 | CETP 1/4885NR1I2 166/4885 |
| US-20100099716-A1 | CETP INHIBITORS | CETP, APOB, MTTP | CETP 1/4885NR1I2 67/4885 |
| US-20160263565-A1 | RUTHENIUM-CATALYZED SYNTHESIS OF BIARYL COMPOUNDS IN WATER | RUVBL2, RUVBL1, CYP2W1 | CETP 4403/4885NR1I2 767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.